Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study (Q57702077)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Giuseppe Remuzzi

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

6

Piero Ruggenenti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

Maria Chiara Sghirlanzoni

29 January 2020

series ordinal

2

object named as

Maria Chiara Sghirlanzoni

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

3

Maddalena Marasà

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Alessandra Salerno

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

21 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Nephrology

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

461-468

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study

29 January 2020

cites work

1 reference

M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy

21 January 2018

1 reference

Mechanisms of disease: Alloimmunization in renal diseases

21 January 2018

1 reference

Rituximab for idiopathic membranous nephropathy

21 January 2018

1 reference

Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.

21 January 2018

1 reference

Rituximab in idiopathic membranous nephropathy: a one-year prospective study

21 January 2018

1 reference

Rituximab therapy for membranous nephropathy: a systematic review

21 January 2018

1 reference

Rituximab treatment of idiopathic membranous nephropathy

21 January 2018

1 reference

Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients

21 January 2018

1 reference

Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs

21 January 2018

1 reference

Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients

21 January 2018

1 reference

Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy

21 January 2018

1 reference

Role of remission clinics in the longitudinal treatment of CKD.

21 January 2018

1 reference

Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial

21 January 2018

1 reference

Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review

21 January 2018

1 reference

Effects of long-term low-dose corticosteroid therapy on humoral immunity.

21 January 2018

1 reference

Effect of Cyclophosphamide on Immunological Control Mechanisms

21 January 2018

1 reference

Rituximab: beyond simple B cell depletion

21 January 2018

1 reference

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

21 January 2018

1 reference

A review of the current use of rituximab in autoimmune diseases

21 January 2018

1 reference

Monoclonal antibodies for podocytopathies: rationale and clinical responses

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy - the importance of early diagnosis illustrated in four cases

21 January 2018

1 reference

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000327611

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21508634%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference